Faculty, Staff and Student Publications

Publication Date

10-2-2024

Journal

Molecular Therapy

Abstract

Patients with cancer of unknown primary (CUP) carry the double burden of an aggressive disease and reduced access to therapies. Experimental models are pivotal for CUP biology investigation and drug testing. We derived two CUP cell lines (CUP#55 and #96) and corresponding patient-derived xenografts (PDXs), from ascites tumor cells. CUP cell lines and PDXs underwent histological, immune-phenotypical, molecular, and genomic characterization confirming the features of the original tumor. The tissue-of-origin prediction was obtained from the tumor microRNA expression profile and confirmed by single-cell transcriptomics. Genomic testing and fluorescence in situ hybridization analysis identified FGFR2 gene amplification in both models, in the form of homogeneously staining region (HSR) in CUP#55 and double minutes in CUP#96. FGFR2 was recognized as the main oncogenic driver and therapeutic target. FGFR2-targeting drug BGJ398 (infigratinib) in combination with the MEK inhibitor trametinib proved to be synergic and exceptionally active, both in vitro and in vivo. The effects of the combined treatment by single-cell gene expression analysis revealed a remarkable plasticity of tumor cells and the greater sensitivity of cells with epithelial phenotype. This study brings personalized therapy closer to CUP patients and provides the rationale for FGFR2 and MEK targeting in metastatic tumors with FGFR2 pathway activation.

Keywords

Animals, Female, Humans, Mice, Cell Line, Tumor, Drug Synergism, Gene Amplification, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Neoplasms, Unknown Primary, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridones, Pyrimidines, Pyrimidinones, Receptor, Fibroblast Growth Factor, Type 2, Xenograft Model Antitumor Assays, cancer of unknown primary, CUP, occult primary tumors, patient-derived xenografts, liquid biopsy, FGFR2, FGFR2 inhibitor, MEK inhibitor, infigratinib, trametinib

DOI

10.1016/j.ymthe.2024.07.011

PMID

39033323

PMCID

PMC11489551

PubMedCentral® Posted Date

7-20-2024

PubMedCentral® Full Text Version

Post-print

fx1 (1).jpg (271 kB)
Graphical Abstract

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.